Superantigens (SAgs) are extremely potent bacterial toxins, which evoke a virulent immune response, inducing nonspecific T-cell proliferation, rapid cytokine release, and lethal toxic shock, for which there is no effective treatment. We previously developed a small molecule, S101, which potently inhibits proliferating T cells. In a severe mouse model of toxic shock, a single injection of S101 given together with superantigen challenge rescued 100% of the mice. Even when given 2 hours after challenge, S101 rescued 40% of the mice. S101 targets the T-cell receptor, inflammatory response, and actin cytoskeleton pathways. S101 inhibits the aryl hydrocarbon receptor, a ligand-activated transcription factor that is involved in the differentiation of T-helper cells, especially Th17, and regulatory T cells. Our results provide the rationale for developing S101 to treat superantigen-induced toxic shock and other pathologies characterized by T-cell activation and proliferation.
activity in vitro and in a murine infection model. Soluble TCR Vβ was also effective against SAgs in vitro and in vivo [9] . Nonetheless, SAg antagonists failed to block T-cell activation or toxic shock induced by staphylococcal enterotoxin B (SEB) in human leukocyte antigen (HLA) class II transgenic mice [10] . Moderate success in mouse models of toxic shock syndrome has been reported using signal transduction inhibitors, such as phosphoinositide 3 kinase/ mechanistic target of rapamycin (PI3K/mTOR), mitogen-activated protein kinase (MAPK), or nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway inhibitors. Rapamycin, an mTOR inhibitor, was effective in a "double-hit" model, in which SAg was first delivered intranasally, followed by intraperitoneal SAg injection [4, 11, 12] . However, "double-hit" challenged mice have less aggressive symptoms than septic shock mouse models, and do not mimic the toxic shock response in humans. Thus, there is still an unmet need for effective treatments for toxic shock.
We recently developed a small molecule, S101, which potently and specifically inhibits proliferating T cells, including cells of the Jurkat T-cell leukemia and Karpas 299 T-cell lymphoma lines, leading to cell cycle arrest at G2 and apoptosis [13] . S101 inhibits activated, but not quiescent, T cells. Here we show that S101 is effective in a severe mouse model of toxic shock and we investigate its mechanism of action. Our data show that S101 is an excellent candidate for the treatment of SAginduced toxic shock, an extreme inflammatory response.
a Ficoll gradient and maintained in RPMI 1640 supplemented with 15 mm HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid; pH 7.4), 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 2 mM l-glutamine, and 5 × 10 -5 2-ME. All media were supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 0.1 mg/mL streptomycin.
Reagents S101 was prepared as described previously [13] . For in vitro studies, S101 was dissolved in dimethyl sulfoxide (DMSO) and diluted such that the vehicle comprised ≤0.01% DMSO. For in vivo studies, S101 was injected in 100% DMSO. SEB and toxic shock syndrome toxin 1 (TSST-1) were purchased from Toxin Technology; anti-aryl hydrocarbon receptor (AhR) antibody (sc-133088) from Santa Cruz Biotechnology; anti-histone H3 (9717) from Cell Signaling Technology; anti-GAPDH (ab8245) and Dylight-488 conjugated antimouse (ab98794) from Abcam; and anti-CD3 (16-0037) from Affymetrix.
Bromodeoxyuridine Uptake
Equal numbers of PBMCs were activated with SEB (100 ng/mL) and treated with vehicle or 1 µM S101, either at the same time as stimulation or 24 hours later. Every 24 hours, cells were removed, washed, counted in the presence of the nonvital stain Trypan blue (Sigma), and resuspended in fresh medium. For each treatment, triplicate samples comprising 10 5 viable cells in 150 µL were plated in a 96-well plate and labeled for 3 hours at 37°C in 5% CO 2 , using the Roche BrdU (bromodeoxyuridine) Cell Proliferation enzyme-linked immunosorbent assay (ELISA) kit. One hundred thirty microliters from each well were transferred to a black-walled 96-well plate and dried. BrdU was detected according to the manufacturer's instructions, and chemiluminescence read in a Luminoskan Ascent luminometer.
Microarray
Custom microarrays were manufactured by Agilent Technologies, using SurePrint technology. Total RNA was extracted using TRIzol Reagent (Ambion) according to the manufacturer's instructions, except that the RNA was precipitated with ethanol. RNA concentration was measured using the NanoDrop ND-1000 UV-Vis Spectrophotometer; RNA quality was monitored using the Agilent 2100 bioanalyzer. All RNA samples used for the study were of high quality, with clear 18S and 28S peaks, and little degraded product (signal:noise >4). Four Agilent 4 × 44k G2519F-014850 oligonucleotide microarray slides (representing 19596 Entrez Gene RNAs from 43376 probes) were used in a dye-swap experiment. Each array compared gene expression between 2 time points. High-quality total RNA samples (10 μg each) were amplified and labeled with Cy5-CTP or Cy3-CTP. The dye-incorporation ratio was determined using a Nanodrop spectrophotometer. For hybridization, 750-ng Cy3-labeled and 750-ng Cy5-labeled samples were mixed and incubated with an Agilent microarray slide for 17 hours at 16°C following saline sodium citrate (SSC) buffer washing. Sample pairs were dyeswapped and processed at the same time. The washed slides were immediately dried and scanned. The raw data were generated using GenePix Pro5.1 software (Axon Instruments). The results were validated by quantitative reverse transcript polymerase chain reaction (qRT-PCR) of selected genes.
Quantitative RT-PCR
RNA was extracted using TRIzol Reagent. RNA (2 μg) was reverse transcribed using M-MLV RT, and messenger RNA (mRNA) levels were measured by qRT-PCR using SYBR Green in a 7900HT Fast Real-Time PCR system (ABI). RT-PCR primers (Supplementary Table 1) were designed for an exonexon boundary when possible. The relative quantities of gene transcripts were analyzed using qBase 1.3.5 software and normalized to the Ubc (encoding human ubiquitin C) and HuPO (human acidic ribosomal protein) transcripts.
Phosphoproteomics

SILAC Labeling and Lysis
Jurkat cells were stable isotope labeling by amino acids in cell culture (SILAC)-labeled in DMEM in which the natural lysine and arginine were replaced by stable isotope-labeled amino acids. Cells were labeled with light (L) amino acids (l-arginine and l-lysine), medium (M) amino acids (l-arginine [ 13 ]). After 10 doublings, the cells were fully labeled and were treated with S101 for 0.5 hour (M), 1 hour (H), or untreated (L). Cells were lysed with 4% sodium dodecyl sulfate (SDS), 100 mM Tris-HCl pH 7.6, 100 mM dithiothreitol (DTT). The lysates were incubated for 5 minutes at 95°C, and briefly sonicated. Equal amounts of protein were mixed prior to protein digestion.
Protein Digestion and Phosphopeptide Enrichment
Proteins were digested with trypsin according to the filter aided sample preparation (FASP) protocol [14] . The peptides were acidified with trifluoroacetic acid (TFA) to pH 2.7 and diluted to 30% acetonitrile (ACN). Peptides were separated into 7 fractions using strong anion exchange chromatography (SCX; Resource S column, GE Healthcare). The flow-through and chromatographic fractions were collected for subsequent phosphopeptide enrichment. Each SCX fraction was incubated with 5 mg of titanium dioxide beads, which had been preincubated with 30 mg/mL dihydroxybenzoic acid. To enrich phosphopeptides from the flow-through, we performed 3 consecutive incubations with the titanium dioxide beads. After 30 minutes of incubation of the peptides with the beads, we performed 2 washes with a buffer containing 30% ACN and 3% TFA and 2 washes with 80% ACN and 0.5% TFA. Phosphopeptides were eluted from the beads with 15% ammonium hydroxide in acetonitrile, then vacuum-concentrated and purified on C18 StageTips.
Liquid Chromatography-Mass Spectrometry Analysis
Peptides were separated by reverse-phase chromatography on a 15-cm column (inner diameter 75 µm, 3 µm ReproSil-Pur C18-AQ media) constructed in-house, using a nanoflow high-performance liquid chromatography (HPLC) system (EASY nLC system; Thermo Scientific). HPLC was coupled on-line, via a nanoelectrospray ion source, to an LTQ-Orbitrap Velos mass spectrometer (Thermo Scientific). Peptides were loaded onto the column with buffer A (0.5% acetic acid), at a flow rate of 500 nL/ minute, and eluted with a 90-minute linear gradient from 5% to 35% buffer B (80% ACN, 0.5% acetic acid) at a flow rate of 250 nL/minute. After the linear gradient, the column was washed reaching 90% buffer B, and then reequilibrated with buffer A.
Mass spectra were acquired in the positive ion mode applying a data-dependent automatic switch between the survey scan (MS) and tandem mass spectrometry (MS/MS) acquisition, with 1 MS scan followed by MS/MS of the 10 most intense ions. Both MS and MS/MS spectra were acquired in the Orbitrap mass analyzer. The target was 1 000 000 ions for the survey scans at a resolution of 30 000 at m/z 400, and 50 000 ions for the MS/ MS scans at a resolution of 7500. Fragmentation was by higher energy collisional dissociation.
Data Analysis
Raw MS files from the LTQ-Orbitrap Velos were analyzed by MaxQuant. MS/MS spectra were searched against the decoy IPI-human database version 3.68 containing forward and reverse protein sequences, by the Andromeda search engine [15] . Parent mass and fragment ions were searched with maximal initial mass deviation of 7 ppm and 20 ppm, respectively. The search included variable modifications of methionine oxidation, N-terminal acetylation, and phospho (STY) and fixed modification of cysteine carbamidomethylation. Peptides of a minimum of 6 amino acids, and a maximum of 2 missed cleavages, were considered for analysis. For peptide, protein, and phosphosite identification, the false discovery rate was set at 0.01. Six hundred seventy-one peptides passed this quality control. Finally, we compared the ratios 0.5 hour/control (M/L), 1 hour/control (H/L), and 1 hour/0.5 hour (H/M). For nonspurious data, we expected that 1 hour/0.5 hour ~ (1 hour/control)/ (0.5 hour/control). We therefore filtered out data where
This left 148 peptides, 71 showing reduced phosphorylation and 67 showing increased phosphorylation after 0.5 hours of treatment with S101. The position of each phosphosite was confirmed using UNIPROT (http://www.uniprot.org/) and/or PhosphoSitePlus (http://www.phosphosite.org/).
Bioinformatics
The data from the microarray and SILAC experiments were analyzed using WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt/), Kyoto Encyclopedia of Genes and Genomes (KEGG;
http://www.genome.jp/kegg/kegg2.html), Search Tool for Retrievement of INteracting Genes/proteins (STRING; http:// string-db.org/), Database for Annotation, Visualization and Integrated Discovery (DAVID; https://david.ncifcrf.gov/) and GProX [16] . Transcription factors were identified using DECipherment Of Dna Elements (DECODE; http://www.sabiosciences.com/chipqpcrsearch.php?app=TFBS) and oPOSSUM (http://opossum.cisreg.ca/oPOSSUM3/).
Cell Fractionation
Cells were washed with phosphate-buffered saline, suspended in hypotonic buffer (10 mM Hepes pH 7.8, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol, and protease inhibitors), and incubated on ice for 5 minutes. NP-40 was added to 0.6% and the mixture vortexed for 30 seconds. The lysate was centrifuged at maximum speed for 1 minute at 4°C in a microcentrifuge. The supernatant, constituting the cytoplasmic fraction, was recentrifuged to remove unlysed cells and mixed with hot Laemmli sample buffer. The pellet was resuspended in the above buffer, vortexed, and centrifuged as before to lyse any remaining cells. The pellet, constituting the nuclear fraction, was extensively washed and suspended in hot Laemmli sample buffer. Anti-GAPDH served as a cytoplasmic marker and anti-histone H3 as a nuclear marker.
Flow Cytometry
Human PBMCs were treated with S101 (1 µM). They were then stained with mouse anti-CD3 followed by Dylight-488 conjugated antimouse antibody, and finally, propidium iodide to exclude dead cells. Cell surface expression of CD3 was analyzed by flow cytometry (BD FACS ARIAIII) using Cytobank (www. cytobank.org) software.
Calcium Mobilization
Jurkat cells were treated with 1 µM S101 or vehicle for 1 hour. The cells were washed and resuspended in fresh RPMI medium supplemented with 1 µM S101 (or vehicle), 2.5 µM Fluo-4AM and probenecid (0.72 mg/mL). After 30 minutes of incubation, the cells were counted and plated in black 96-well plates (Greiner) at 50 000 cells/ well. Immediately before reading fluorescence in a BioTek plate reader, the cells were activated with antibody to CD3 (C305).
Animal Experiments
Animal experiments were performed according to the regulations of the Hebrew University Ethical Committee. Mice were challenged with SAgs and treated with S101 as described in the figure legends. Survival curves were plotted using GraphPad Prism5. P values were calculated according to the log-rank Mantel-Cox test.
RESULTS
S101 Inhibits SAg-Activated PBMCs
In our earlier studies, we found that S101 inhibited the proliferation of T cells that had been activated by a variety of methods [13] . As SAGs are known to act on T cells [3, 5, 17, 18] , we hypothesized that S101 would similarly inhibit SAg-induced PBMC proliferation. We first tested the effect of S101 on human PBMCs in vitro. SEB and TSST-1 strongly stimulated PBMC proliferation ( Figure   1A and 1B). As hypothesized, the viability of SAG-stimulated cells was strongly inhibited by S101, with an half maximal inhibitory concentration (IC 50 ) of 360 nM for SEB stimulation and of 203 nM for TSST-1 ( Figure 1A and 1B . S101 inhibits the proliferation of peripheral blood mononuclear cells (PBMCs) stimulated by superantigen (SAg) toxins. A and B, 100 000 PBMCs were seeded into white 96-well plates and grown overnight. The cells were then challenged with 100 ng/mL of staphylococcal enterotoxin B (SEB) (A) or toxic shock syndrome toxin 1 (TTST-1) (B) and treated with S101 at the indicated concentrations. Seventy-two hours later, cell viability was measured using CellTiter Glo (Promega). Black bars show nonstimulated PBMCs, gray bars show SAg-stimulated PBMCs. P < .0001 (0.5 µM vs untreated [UT]). C and D, 3 × 10 6 PBMCs per well were plated in 4 replicate 6-well plates (4 mL/well) and treated with vehicle, SEB (100 ng/mL), S101 (1 µM), both SEB and S101, or SEB initially with S101 added after 24 h. Every 24 h, the cells from 1 plate were harvested. C, Viable cells were counted in the presence of Trypan blue. D, The cells were adjusted to give the same concentration of viable cells in each sample. Bromodeoxyuridine (BrdU) uptake was measured on triplicate samples containing 1.1 × 10 6 live cells. P = .0056 (SEB vs SEB + S101 at 72 h). E, S101 inhibits tumor necrosis factor alpha (TNF-α) secretion. A total of 200 000 freshly isolated PBMCs were seeded into 96-well plates, in 200 μL medium per well. Twenty-four hours later, SEB and S101 were added simultaneously at the indicated concentrations. Four hours later, the plates were centrifuged, the medium was extracted, and human TNF-α was measured by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (Peprotech) P = .013 (0.5 vs 0 µM S101). Representative experiments are shown, from at least 3 independent experiments. P values were calculated using 2-tailed t tests. *P < .05, **P < .01, ***P < .001.
were unaffected by S101 ( Figure 1A and 1B) . Both CD4 + and CD8 + SEB-stimulated human T cells were strongly inhibited by S101, as were mouse CD4 + and CD8 + T cells stimulated by other means (Supplementary Figure 1) . To test whether S101 affected the proliferation of the SAG-stimulated PBMCs, we treated SEB-stimulated PBMCs with S101 or vehicle over the course of several days, and compared BrdU uptake by equal numbers of viable cells, counted in the presence of Trypan blue ( Figure 1C  and 1D ). In agreement with the data of McLeod et al [19] , BrdU uptake increased sharply about 48 hours after SEB stimulation, and this was also reflected in the number of viable cells. BrdU uptake was significantly inhibited when S101 was also added to the cells, either at the time of initial stimulation with SEB or 24 hours later. Moreover, CFSE depletion was inhibited in mouse splenocytes that were stimulated to proliferate in the presence of S101 (Supplementary Figure 2) . Thus, S101 inhibits the proliferation of SEB-stimulated PBMCs. We next tested whether S101 prevented the secretion of TNF-α, the major cytokine implicated in lethal toxic shock [7, 20] . Following SEB activation of PBMCs, the secretion of TNF-α into the growth medium was enhanced 1000-fold. This effect was significantly reduced by S101 treatment ( Figure 1E ). Thus, S101 counters the hyperstimulation of human PBMCs by SAgs, inhibiting both SAg-induced proliferation and the consequent cytokine release.
S101 Rescues Mice From SAg Toxicity
We next tested whether S101 could prevent SAg-induced toxicity in vivo. To this end, we invoked a stringent animal model of toxic shock [21] , in which mice are sensitized with d-galactosamine prior to SAg injection. SAgs possess much higher affinity to human MHC-II than to mouse MHC-II, so human peripheral lymphocytes are stimulated at concentrations of SAg that are several orders of magnitude lower than the concentrations that stimulate mouse peripheral lymphocytes [2] . Sensitization of mice with d-galactosamine prior to SAg injection results in a much stronger reaction to the SAg and a better approximation of human toxic shock syndrome. Massive numbers of T cells are activated and the levels of TNF-α and other cytokines in blood rise rapidly. Acute liver failure and death ensue within 24-48 hours.
Using this model, 70% of SEB-challenged mice died within 24 hours of SEB injection (Figure 2A ). TSST-1 was even more lethal: 90% of the mice died within 24 hours ( Figure 2B ). Remarkably, a single injection of S101, administered together with the SAg, rescued 100% of the SEB-challenged mice (Figure 2A ). S101 was effective even when given after the SAg challenge: 40% of the mice survived following a single injection of S101, administered 2 hours after TSST-1 ( Figure 2B ).
We reasoned that S101 alleviated SAg toxicity by preventing the cytokine storm. Since TNF-α is a major cause of SAg toxicity, we looked at the levels of TNF-α in the blood of SAg-challenged mice. In the blood of control mice challenged with SEB, high levels of TNF-α were measured 6 hours after SEB challenge, as expected. In the blood of mice that were treated with S101, the ; n = 9); S101 (100 mg/kg in 50 µL 100% DMSO, IP) concurrently with SEB ("0 min"; n = 8); S101, 30 min after SEB (n = 8); S101, 60 min after SEB (n = 9). Mice were monitored at least 3 times/d for the appearance of toxic shock symptoms. (P value for concurrent S101 vs vehicle = .0057; P value for 30-minute delayed S101 vs vehicle = .0183) B, Mice were sensitized as above and challenged with 7.5 µg/mouse toxic shock syndrome toxin 1. The mice were divided into 5 groups (n = 8) and treated with S101 (100 mg/kg) at the indicated time intervals after the challenge (P = .0002). C, Fifteen-to 16-week-old female Balb/c mice (4 groups, n = 5) were sensitized with d-galactosamine (20 mg/ mouse) and challenged with SEB (7.5 μg/ mouse). S101 (100 mg/kg) was injected simultaneously with SEB. Blood from the mice was taken 6 and 24 hours after the challenge. The plasma was extracted and subjected to mouse tumor necrosis factor alpha (TNF-α) ELISA (Peprotech) (P < .0001).
levels of TNF-α were about 10-fold lower 6 hours after challenge, and had dropped to basal levels by 24 hours after challenge ( Figure 2C ). Thus, S101 effectively precluded cytokine storm and protected the mice from SAg toxicity.
S101 Inhibits Signaling Downstream of the TCR
The profound effects of S101 in a severe model of toxic shock spurred us to investigate the mechanism of action of S101. In its chemical structure S101, a quinazoline, bears similarity to many kinase inhibitors. However, when S101 was tested in vitro on the recombinant kinase domains from >130 proteins, none of these showed significant inhibition (data not shown).
We therefore turned to mass spectrometry-based phosphoproteomics to look at the phosphorylation of whole proteins in the cellular context in an unbiased manner. Using SILAC, we compared lysates from labeled and unlabeled Jurkat cells that were treated with S101 (0.5 µM) for 0, 0.5, 1, or 2 hours. After stringent filtration of the results, we compiled a list of 148 phosphopeptides-representing 116 proteins-that were significantly affected by S101 (Supplementary Table 1 ). More than 40% of these phosphorylation sites overlapped with sites that are affected in Jurkat cells during TCR signaling [22, 23] (Supplementary Table 1 ). Two pathways, TCR signaling and regulation of actin cytoskeleton, were significantly enriched among the 116 proteins (Table 1 ; Supplementary Figure 3) . The phosphorylation of the PAK kinases PAK2 and PAK4, which connect between TCR signaling and regulation of the actin cytoskeleton, was affected by S101. These data imply that S101 inhibits TCR signaling and the consequent remodeling of the actin cytoskeleton.
The remodeling of the cytoskeleton following TCR activation is intimately associated with rapid calcium mobilization [24] . S101 inhibited calcium mobilization in Jurkat cells activated by anti-CD3 antibody ( Figure 3A) . The inhibition of calcium mobilization is an important anti-inflammatory effect of S101.
According to the SILAC results, the phosphorylation of Ser148 on CD3γ, a subunit of the TCR, was increased (~1.5-fold) following S101 treatment (Table 1 ). Phosphorylation at this residue leads to receptor internalization, attenuating the TCR activation signal [25, 26] . To test whether CD3 expression at the cell surface was affected by S101, we performed fluorescence-activated cell sorting. There was a significant decrease in CD3 levels on the surface of human PBMCs that were treated with S101 ( Figure 3B; Supplementary Figure 4) . We note that Karpas 299 lymphoma cells do not express the TCR or surface CD3 [27] , yet are sensitive to S101. This may indicate that other T-cell-specific factors are also affected by S101, or may reflect cytoplasmic expression of CD3 [28] . Taken together, our data show that S101 counteracts TCR signaling, inhibiting the proliferation of activated T cells.
S101 Inhibits the Inflammatory Response via Inhibition of the Aryl Hydrocarbon Receptor
We complemented the phosphoproteomic study with comprehensive gene expression microarray analysis. We compared mRNAs from human PBMCs treated with 0.5 µM S101 for 30 hours, to see downstream effects of transcriptional regulation. 53 probes, representing 28 genes, showed significant changes in expression (Table 2) . Biological processes that were significantly enriched included inflammatory response (7 genes, Q value = 0.001) and locomotion (11 genes, Q value = 0.0003). Molecular functions that were enriched included cytokine activity (4 genes, Q value = 0.0029). These processes correlate with the pathways enriched in the proteomics data, and with the known involvement of inflammation and cytokine activity in toxic shock syndrome.
Analyzing the upstream regulators of the genes that were affected in the microarray study, we noticed that 7 of the 28 genes affected by S101 were known targets of the transcription factor AhR (Table 2) . Moreover, 14 of the affected genes had AhR binding elements (XRE) in their promoters (Z score = 4.1 [oPOSSUM]). Originally identified as a mediator of the adaptive response to environmental pollutants, the AhR has been intensively studied recently for its roles in cellular proliferation and inflammation. The structures of S101 and of known AhR agonists and antagonists [29] showed strong similarities. The AhR has a central role in the control of inflammation: It promotes the polarization of Tregs and of Th17 and is involved in maintaining the Th1/Th2 balance [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] . The AhR has additional functions, including calcium mobilization [39] . Because of the role of the AhR in lymphocyte development and its interactions with TNF-α and IFN-γ [40] [41] [42] [43] [44] [45] , which are strongly implicated in SAg toxicity, we decided to examine whether the AhR is a bona fide target of S101. Of the 7 AhR targets that were affected by S101 in the microarray, 6 showed reduced expression following treatment. The seventh, IL6, which is suppressed by an AhR agonist [33, 43, 46, 47] , showed increased expression in the treated samples. To validate the microarray data, we used qRT-PCR to confirm the inhibition of known AhR targets in human PBMCs (Table 3) . Among the AhR targets that were repressed by S101 was IFN-γ, which as stated above, plays a key role in SAg toxicity.
Following ligand binding, the AhR translocates into the nucleus, where it acts as a transcriptional co-factor. To further examine the effect of S101 on the AhR, we looked at its cellular localization. In unstimulated Karpas 299 cells, S101 treatment led to the retention of the AhR in the cytosol, and to its depletion from the nucleus ( Figure 4A ). The treatment of Karpas 299 cells with the AhR ligand, ITE [48, 49] , led to the translocation of the AhR into the nucleus, where it reached a maximum after 1 hour of treatment and was then degraded. Levels of CYP1B1, an AhR target, increased after 3 hours of stimulation with ITE. The decreased levels of the AhR probably reflect feedback inhibition by AhR substrates, such as CYP1A1 and CYP1B1 [35] . The pretreatment of Karpas 299 cells with S101 prevented CYP1B1 induction and slowed down the nuclear degradation of the AhR ( Figure 4B ). This effect was not seen when ITE was added before or simultaneously with S101 ( Figure 4B ), suggesting that S101 affects the AhR in its nonactivated state and prevents its activation. Vehicle S101 2h A B Figure 3 . A, S101 reduces calcium mobilization. Jurkat cells were treated in triplicate with 1 µM S101 for 1 h, prior to loading with Fluo-4AM (2.5 µM), as described in the Materials and Methods. Cells were activated with antibody against CD3 (C305), immediately before the first fluorescence reading. Fluorescence was read every 15 seconds. A representative experiment is shown (of 2 independent experiments). B, S101 reduces cell surface expression of CD3. Human PBMCs were treated with vehicle or S101 (1 µM) for 2 h, the cells were stained for CD3, and CD3 expression on the cell surface was evaluated by flow cytometry. A representative experiment is shown (of 3 independent experiments). Abbreviation: MFI, mean fluorescence intensity. In Karpas 299 cells, where basal levels of the AhR are high, ITE had only a slight effect on cellular proliferation. In Jurkat cells, however, where AhR levels are very low, ITE treatment induced cell proliferation, which was counteracted by treatment with S101 ( Figure 4C ). These findings support the bioinformatics and indicate that the effect of S101 on T-cell proliferation is mediated partly via the AhR.
CONCLUSIONS
In summary, S101 prevents SAg-induced cytokine storm and toxic shock in a severe mouse model, even when administered after the SAg challenge. S101 dampens the TCR response and its downstream pathways, inhibiting SAg-activated T-cell proliferation. A multitargeted inhibitor, S101 affects a number of pathways that are related to the activation of T-cells. The mechanism of S101 is unlike that of immunosuppressive drugs such as rapamycin, in that S101 does not affect IL-2 secretion [13] . S101 inhibits T-cell hyperactivation through inhibition of TCR and AhR signaling, and may have additional targets still to be identified. Although the AhR is expressed in many eukaryotic tissues, the antiproliferative and proapoptotic effects of S101 appear to be limited to cells of the hematopoietic system, especially T cells. This is likely because S101 interacts, directly or indirectly, with elements of the TCR and CD3 complexes. . S101 counteracts the effects of the aryl hydrocarbon receptor (AhR) agonist, ITE. A, Karpas 299 cells were treated with S101 (1 µM), and cytoplasmic and nuclear fractions were separated and subjected to Western blot analysis. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as a marker for the cytoplasmic fractions and histone H3 as a marker for the nuclear fractions. B, S101 prevents AhR activation by ITE. Karpas 299 cells were treated with ITE (0.1 µM) for 0.5-4 h, pretreated with S101 (1 µM) for 2 h followed by ITE for 0.5-4 h, or co-treated with S101 plus ITE for 4 h, prior to addition of ITE. Cells were fractionated and analyzed by Western blot. C, Jurkat or Karpas 299 cells were treated overnight with ITE (0.1 µM) or co-treated with ITE (0.1 µM) plus S101 at the indicated concentrations. Cells were labeled with bromodeoxyuridine (BrdU) for 4 h and analyzed for luminescence using the Cell Proliferation enzyme-linked immunosorbent assay kit (Roche). (P value for activation by ITE for Jurkat = .0152, for Karpas = .063, not significant; P value for inhibition at 0.5 µM S101 for Jurkat = .014, for Karpas = .0014) Abbreviations: CF, cytoplasmic fraction; CYP, cytochrome P450; NF, nuclear fraction, UT, untreated; V, vehicle; WC, whole cell lysate.
A treatment that affects only proliferating T cells can avoid general immune suppression. The remarkable ability of S101 to discriminate between active and resting PBMCs, and its inactivity toward many other cell types, render it a strong candidate for therapy, not only for toxic shock but also for other disorders involving pathological activation of T cells, including T-cell lymphomas and autoimmune conditions.
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